Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Gallium-citrate PET/CT in Orthopedic Infections
NCT03123289Phase 2Terminated
- Sponsor
- Rutgers University
- Start
- Mar 2017
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms), sponsored by Rutgers University. Primary endpoint: 68Gallium-citrate and 18F-FDG uptake at 1 year. Started Mar 2017; status: terminated.
Beyond the preview
Go deeper on NCT03123289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123289.